Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Macitentan (Opsumit®) is recommended as an option for use within NHS Wales as monotherapy or in combination for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | macitentan (Opsumit®) | ||
| Formulation | 10 mg film-coated tablet | ||
| Reference number | 711 | ||
| Indication | Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, as a monotherapy or in combination |
||
| Company | Actelion Pharmaceuticals UK Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 4215 | ||
| NMG meeting date | 04/11/2015 | ||
| AWMSG meeting date | 09/12/2015 | ||
| Ratification by Welsh Government | 06/01/2016 | ||
| Date of issue | 11/01/2016 | ||
| Date of last review | 13/06/2019 | ||
| Commercial arrangement | WPAS | ||